Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000. It is widely used in veterinary medicine as an antiprotozoal agent to treat and prevent parasitic infections like coccidiosis in poultry and cryptosporidiosis in calves. Its therapeutic use is listed as antiparasitics and antiprotozoals. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Halofuginonum, Halocur and Halofuginon. Its PubChem CID is 456390.
Halofuginone
| CAS No | 55837-20-2 |
|---|---|
| Molecular Formula | C16H17BrClN3O3 |
| Molecular Weight | 414.7 g/mol |
| Synonyms | 7-bromo-6-chloro-3-[3-[(2R,3S)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression.
The listed CAS number is 55837-20-2.
The listed molecular formula is C16H17BrClN3O3.
The listed molecular weight is 414.7 g/mol.
7-bromo-6-chloro-3-[3-[(2R,3S)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one.
The source lists Halofuginonum, Halocur and Halofuginon.